These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24029707)

  • 41. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
    Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
    Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung.
    Pelosi G; Scarpa A; Manzotti M; Veronesi G; Spaggiari L; Fraggetta F; Nappi O; Benini E; Pasini F; Antonello D; Iannucci A; Maisonneuve P; Viale G
    Mod Pathol; 2004 May; 17(5):538-46. PubMed ID: 14990969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status.
    Sousa V; Rodrigues C; Silva M; Alarcão AM; Carvalho L
    Rev Port Pneumol (2006); 2015; 21(3):113-25. PubMed ID: 25926253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
    J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
    Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
    Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung.
    Rossi G; Marchioni A; Milani M; Scotti R; Foroni M; Cesinaro A; Longo L; Migaldi M; Cavazza A
    Am J Clin Pathol; 2004 Dec; 122(6):884-93. PubMed ID: 15595193
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung.
    Sakai Y; Nakai T; Ohbayashi C; Imagawa N; Yanagita E; Satake R; Nitta A; Kajimoto K; Sakuma T; Itoh T
    Int J Surg Pathol; 2013 Oct; 21(5):476-82. PubMed ID: 23794492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
    Chiosea S; Shuai Y; Cieply K; Nikiforova MN; Dacic S
    Hum Pathol; 2010 Aug; 41(8):1053-60. PubMed ID: 20381121
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort.
    Mansuet-Lupo A; Bobbio A; Blons H; Becht E; Ouakrim H; Didelot A; Charpentier MC; Bain S; Marmey B; Bonjour P; Biton J; Cremer I; Dieu-Nosjean MC; Sautès-Fridman C; Régnard JF; Laurent-Puig P; Alifano M; Damotte D
    Chest; 2014 Sep; 146(3):633-643. PubMed ID: 24676429
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas.
    Noh S; Shim H
    Lung Cancer; 2012 Apr; 76(1):51-5. PubMed ID: 21978426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.
    Okamoto T; Kohno M; Ito K; Takada K; Katsura M; Morodomi Y; Toyokawa G; Shoji F; Maehara Y
    Anticancer Res; 2017 Apr; 37(4):1729-1735. PubMed ID: 28373435
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MicroRNAs associated with increased AKT gene number in human lung carcinoma.
    Goto A; Dobashi Y; Tsubochi H; Maeda D; Ooi A
    Hum Pathol; 2016 Oct; 56():1-10. PubMed ID: 27189341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas.
    Woo T; Okudela K; Yazawa T; Wada N; Ogawa N; Ishiwa N; Tajiri M; Rino Y; Kitamura H; Masuda M
    Lung Cancer; 2009 Sep; 65(3):355-62. PubMed ID: 19162366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy.
    Chang YL; Wu CT; Shih JY; Lee YC
    Ann Surg Oncol; 2011 Oct; 18(10):2952-60. PubMed ID: 21409490
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer.
    Sasaki H; Hikosaka Y; Kawano O; Moriyama S; Yano M; Fujii Y
    J Thorac Oncol; 2011 Jan; 6(1):15-20. PubMed ID: 21150464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.